ORXOY

Orexo AB (publ) [ORXOY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ORXOY Stock Summary

Earnings have grown 10.5% per last year.

EPS has been increasing for the past 3 quarters (Quarter statements)

Has a high level of debt. Debt-to-Equity ratio of 4.18 is considered high.

Earnings are expected to fall -100% next year

Profit margins (-0.31%) are lower than the previous year (-0.28%)

ORXOY has less than 1 year of cash runway

In the News

02:12 27 Sep 2023 ORXOY

MODIA™ paper published in the Journal of Medical Internet Research Mental Health

UPPSALA, Sweden, Oct. 18, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announced the publication of a manuscript, "A Personalized, Interactive, Cognitive-Behavioral Therapy-Based Digital Therapeutic (MODIA™) for Adjunctive Treatment of Opioid Use Disorder: Development Study," in the Journal of Medical Internet Research (JMIR) Mental Health.

02:47 27 Sep 2023 ORXOY

Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial

UPPSALA, Sweden, July 16, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully initiated the pivotal trial (OX124-002) for its lead pharmaceutical pipeline asset, OX124.

02:21 27 Sep 2023 ORXOY

Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

UPPSALA, Sweden, July 1, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the enrollment of the first participant in the pivotal study of digital therapeutic modia™, in combination with sublingual buprenorphine/naloxone, as part of a clinician-supervised medication-assisted treatment program for the treatment of opioid use disorder (OUD).

02:50 27 Sep 2023 ORXOY

Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management

UPPSALA, Sweden, Feb. 10, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the company will collaborate with ApexB.io and Magellan Rx Management to further research on the use of modia™, a digital therapeutic designed for individuals with opioid use...

10:45 27 Sep 2023 ORXOY

Orexo calls for redemption of its outstanding bonds and obtains temporary waiver

UPPSALA, Sweden, Feb. 5, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) ") has today given notice to all holders of the Company's maximum SEK 500,000,000 senior unsecured callable floating rate bonds 2017/2021 with ISIN SE0010494450 (the "Bonds")...

12:10 27 Sep 2023 ORXOY

Orexo has successfully issued senior unsecured callable floating rate bonds

UPPSALA, Sweden, Feb. 4, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) has successfully issued senior unsecured callable floating rate bonds in the amount of SEK 500 million, under a framework of SEK 1,000 million with final maturity in February...

02:15 27 Sep 2023 ORXOY

Orexo contemplates issue of senior unsecured callable floating rate bonds

UPPSALA, Sweden, Feb. 1, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) has mandated ABG Sundal Collier AB to arrange a series of fixed income investor meetings in the Nordics, commencing on 1 February 2021. An issue of SEK denominated senior...

02:17 27 Sep 2023 ORXOY

Orexo strengthens IP rights for overdose rescue drug OX124

UPPSALA, Sweden, Jan. 27, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the company has further strengthened the intellectual property (IP) for its flagship pharmaceutical pipeline asset OX124, a naloxone rescue medication for the treatment of...

ORXOY Financial details

Company Rating

Buy

Market Cap

54.2M

Income

-194.8M

Revenue

633.5M

Book val./share

3.6

Cash/share

7.3

Dividend

Dividend %

Employees

120

Optionable

Shortable

Yes

Earnings

31 Mar 2023

P/E

-1.48

Forward P/E

PEG

1.15

P/S

0.96

P/B

2.32

P/C

0.1

P/FCF

-2.9

Quick Ratio

0.83

Current Ratio

1.87

Debt / Equity

4.18

LT Debt / Equity

EPS (TTM)

-5.67

EPS next Y

EPS next Q

EPS this Y

-20.58%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

-4.43%

Revenue Q/Q

-0.69%

EPS Q/Q

-80.11%

SMA20

-44.44%

SMA50

SMA100

Inst Own

Inst Trans

ROA

-21%

ROE

-105%

ROC

-0.36%

Gross Margin

84%

Oper. Margin

-35%

Profit Margin

-31%

Payout

Shs Outstand

72.53M

Shs Float

21.64M

Target Price

52W Range

0.76-2.82

52W High

52W Low

RSI

Rel Volume

Avg Volume

Volume

1.63K

Perf Week

-21.81%

Perf Month

-55.56%

Perf Quarter

Perf Half Y

-55.56%

Beta

0.665165

Volatility

0.07%, 0.35%

Prev Close

-21.81%

Price

0.76

Change

-21.81%

ORXOY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	22.66	24.4	19.29	16.46	18.17
Net income per share	3.99	6.33	-2.45	-6.51	-5.17
Operating cash flow per share	7	8.29	0.49	-6.67	-4.56
Free cash flow per share	6.9	7.37	-5.03	-8.21	-5.25
Cash per share	17.07	23.59	14.69	14.69	10.24
Book value per share	13.78	20.4	16.24	10.19	5.64
Tangible book value per share	10.77	17.11	9.42	2.94	-0.68
Share holders equity per share	13.78	20.4	16.24	10.19	5.64
Interest debt per share	9.75	10.51	8.93	16.86	16.52
Market cap	1.94B	2.14B	1.52B	1.25B	620.23M
Enterprise value	1.67B	1.66B	1.31B	1.29B	1.03B
P/E ratio	14.07	9.75	-18.02	-5.57	-3.49
Price to sales ratio	2.48	2.53	2.29	2.2	0.99
POCF ratio	8.02	7.44	90.54	-5.44	-3.96
PFCF ratio	8.14	8.37	-8.8	-4.42	-3.44
P/B Ratio	4.07	3.02	2.72	3.56	3.2
PTB ratio	4.07	3.02	2.72	3.56	3.2
EV to sales	2.13	1.97	1.97	2.29	1.65
Enterprise value over EBITDA	12.9	5.77	77.79	-9.14	-13.87
EV to operating cash flow	6.9	5.79	77.79	-5.64	-6.56
EV to free cash flow	7.01	6.52	-7.56	-4.58	-5.69
Earnings yield	0.07	0.1	-0.06	-0.18	-0.29
Free cash flow yield	0.12	0.12	-0.11	-0.23	-0.29
Debt to equity	0.67	0.49	0.52	1.57	2.78
Debt to assets	0.25	0.23	0.24	0.43	0.49
Net debt to EBITDA	-2.08	-1.64	-12.76	-0.33	-5.5
Current ratio	2.19	2.65	1.38	2.28	1.91
Interest coverage	5.81	11.86	-1.36	-7.98	-7.71
Income quality	2.53	1.24	-0.84	1.07	0.85
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.21	0.17	0.15	0.27	0.32
Research and developement to revenue	0.21	0.21	0.34	0.48	0.51
Intangibles to total assets	0.08	0.08	0.19	0.2	0.2
Capex to operating cash flow	-0.01	-0.11	-11.29	0.23	0.15
Capex to revenue	0	-0.04	-0.29	-0.09	-0.04
Capex to depreciation	-0.17	-0.78	-4.88	-1	-0.35
Stock based compensation to revenue	0	0.01	-0.03	0	0
Graham number	35.17	53.9	29.94	38.63	25.62
ROIC	0.18	0.2	-0.05	-0.24	-0.29
Return on tangible assets	0.12	0.16	-0.08	-0.22	-0.2
Graham Net	-3.88	8.44	1.41	-5.01	-8.57
Working capital	576.1M	760.2M	230.3M	485.3M	349.6M
Tangible asset value	372.2M	592.4M	324.2M	100.8M	-23.5M
Net current asset value	248.9M	426.5M	157.2M	-58.6M	-179.6M
Invested capital	0.67	0.49	0.52	1.57	2.78
Average receivables	0	136.25M	245.15M	243.5M	289.1M
Average payables	46.6M	48.55M	48.2M	48.1M	67.9M
Average inventory	211.9M	152.7M	120.1M	100.35M	83.45M
Days sales outstanding	0	117.73	119.8	173.91	180.66
Days payables outstanding	101.34	170.75	261.51	227.6	308.08
Days of inventory on hand	368.82	455.56	603.14	426.99	265.39
Receivables turnover	0	3.1	3.05	2.1	2.02
Payables turnover	3.6	2.14	1.4	1.6	1.18
Inventory turnover	0.99	0.8	0.61	0.85	1.38
ROE	0.29	0.31	-0.15	-0.64	-0.92
Capex per share	-0.1	-0.92	-5.51	-1.54	-0.7

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
Revenue per share	4.3	4.68	4.54	4.62	4.58
Net income per share	-1.04	-0.77	-2.67	-1.86	-0.37
Operating cash flow per share	0.42	-1.77	-1.42	-1.79	-0.37
Free cash flow per share	0.29	-1.81	-1.78	-1.82	-0.68
Cash per share	13.61	12.92	10.24	8.12	7.3
Book value per share	8.99	8.68	5.64	3.76	3.6
Tangible book value per share	8.99	8.68	-0.68	3.76	3.6
Share holders equity per share	8.99	8.68	5.64	3.76	3.6
Interest debt per share	16.2	16.57	17.62	15.71	15.11
Market cap	776.64M	803.79M	620.4M	608.23M	284.05M
Enterprise value	1.08B	1.22B	1.03B	996.23M	550.05M
P/E ratio	-5.44	-7.58	-1.69	-2.38	-5.64
Price to sales ratio	5.25	4.99	3.98	3.83	1.8
POCF ratio	53.56	-13.24	-12.71	-9.87	-22.37
PFCF ratio	77.66	-12.9	-10.17	-9.75	-12.09
P/B Ratio	2.51	2.69	3.2	4.71	2.29
PTB ratio	2.51	2.69	3.2	4.71	2.29
EV to sales	7.29	7.6	6.59	6.27	3.49
Enterprise value over EBITDA	-33.13	-37.76	-87.85	-24.24	100.01
EV to operating cash flow	74.26	-20.15	-21.06	-16.17	-43.31
EV to free cash flow	107.67	-19.64	-16.85	-15.97	-23.41
Earnings yield	-0.05	-0.03	-0.15	-0.11	-0.04
Free cash flow yield	0.01	-0.08	-0.1	-0.1	-0.08
Debt to equity	1.76	1.82	2.78	4.11	4.18
Debt to assets	0.43	0.45	0.49	0.56	0.56
Net debt to EBITDA	-9.23	-12.95	-34.82	-9.44	48.36
Current ratio	2.05	2.21	1.91	1.93	1.87
Interest coverage	-4.04	-1.82	-1.54	-6.45	-4.64
Income quality	-0.29	1.22	0.69	1.04	0.98
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.35	0.34	0.41	0.42	0.24
Research and developement to revenue	0.55	0.48	0.57	0.49	0.48
Intangibles to total assets	0.19	0.19	0.2	0.22	0.21
Capex to operating cash flow	-0.31	0.03	0.25	0.01	0.85
Capex to revenue	-0.03	-0.01	-0.08	-0.01	-0.07
Capex to depreciation	-0.26	-0.09	-0.68	-0.04	-0.58
Stock based compensation to revenue	0	0	0	0	0
Graham number	14.49	12.27	18.42	12.54	5.44
ROIC	-0.05	-0.07	-0.13	-0.08	-0.02
Return on tangible assets	-0.03	-0.03	-0.1	-0.09	-0.02
Graham Net	-13.16	-12.13	-8.56	-14.81	-15.06
Working capital	450.9M	452.4M	349.6M	283.6M	264.7M
Tangible asset value	73.4M	68.8M	-23.5M	-78.1M	-74M
Net current asset value	-80.1M	-77.4M	-179.6M	-230.9M	-234.4M
Invested capital	1.76	1.82	2.78	4.11	4.18
Average receivables	0	0	154.5M	154.5M	0
Average payables	0	0	43.3M	43.3M	0
Average inventory	81M	86.55M	81.65M	69.65M	65.9M
Days sales outstanding	0	0	178.27	0	0
Days payables outstanding	0	0	300.93	0	0
Days of inventory on hand	358.3	285.11	259.23	202.89	351.1
Receivables turnover	0	0	0.5	0	0
Payables turnover	0	0	0.3	0	0
Inventory turnover	0.25	0.32	0.35	0.44	0.26
ROE	-0.12	-0.09	-0.47	-0.49	-0.1
Capex per share	-0.13	-0.05	-0.36	-0.02	-0.31

ORXOY Frequently Asked Questions

What is Orexo AB (publ) stock symbol ?

Orexo AB (publ) is a SE stock and trading under the symbol ORXOY

What is Orexo AB (publ) stock quote today ?

Orexo AB (publ) stock price is $0.76 today.

Is Orexo AB (publ) stock public?

Yes, Orexo AB (publ) is a publicly traded company.

Something similar

Top by Market Cap

BRYN.DE

RILYN

Company Profile

Volume Average 43
Market Capitalization 54.2M
Employee 120
CEO Mr. Nikolaj Sorensen
Headquarters Uppsala,SE
IPO Date 2018-03-15
Website https://www.orexo.com

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.